Paul Choi
Stock Analyst at Goldman Sachs
(3.53)
# 798
Out of 4,842 analysts
108
Total ratings
52.86%
Success rate
3.81%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $4.05 | -25.93% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $1.16 | +589.66% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $4.08 | +22.55% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $7.29 | +9.81% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $28.49 | +82.52% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $4.76 | +341.18% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.54 | +40.52% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $0.83 | +259.41% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $9.50 | +5.26% | 4 | Apr 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $20 → $7 | $11.29 | -38.00% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $159.41 | +41.15% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $74.18 | +92.77% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $47.22 | -11.05% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $30.28 | +98.15% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.21 | +43.83% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $27.26 | +17.39% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $32.26 | +54.99% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.30 | +341.86% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.32 | +528.93% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $0.90 | +2,677.16% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $15.06 | +1,028.82% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $3.37 | +137.39% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $29.54 | +11.71% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $46.68 | +139.93% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $123.03 | +9.73% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.70 | +2,760.00% | 2 | Mar 30, 2020 |
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $4.05
Upside: -25.93%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.16
Upside: +589.66%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $4.08
Upside: +22.55%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $7.29
Upside: +9.81%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $28.49
Upside: +82.52%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $4.76
Upside: +341.18%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.54
Upside: +40.52%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $0.83
Upside: +259.41%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $9.50
Upside: +5.26%
Amarin Corporation
Apr 17, 2025
Maintains: Sell
Price Target: $20 → $7
Current: $11.29
Upside: -38.00%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $159.41
Upside: +41.15%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $74.18
Upside: +92.77%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $47.22
Upside: -11.05%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $30.28
Upside: +98.15%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.21
Upside: +43.83%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $27.26
Upside: +17.39%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $32.26
Upside: +54.99%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.30
Upside: +341.86%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.32
Upside: +528.93%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $0.90
Upside: +2,677.16%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $15.06
Upside: +1,028.82%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $3.37
Upside: +137.39%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $29.54
Upside: +11.71%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $46.68
Upside: +139.93%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $123.03
Upside: +9.73%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.70
Upside: +2,760.00%